loader2
Login Open ICICI 3-in-1 Account
Text Size
Text to Speech
Color Contrast
Pause Animations

Anthem Biosciences Results: Latest Quarterly Results & Analysis

Open Free Trading Account Online with ICICIDIRECT
+91
Anthem Biosciences Ltd. 05 Feb 2026 14:34 PM

Q3FY26 Quarterly Result Announced for Anthem Biosciences Ltd.

Pharmaceuticals company Anthem Biosciences announced Q3FY26 results

  • Consolidated Revenue from Operations was Rs 4,232 million for the quarter.
    • CRDMO business delivered Rs 3,332 million revenues.
    • Specialty Ingredients delivered Rs 899 million revenues.
  • EBITDA was Rs 1,907 million, with EBITDA margins at 41.8%.
    • EBITDA for Q3FY26 includes Other Income of Rs 335 million (Q3FY25: Rs 244 million).
      • Other Operating Income on account of forex gain (net) and RoDTEP incentives is Rs 64 million (Q3FY25: Rs 98 million).
      • Financial and other Non-Operating Income is Rs 271 million (Q3FY25: Rs 146 million).
  • PBT before exceptions items was Rs 1,558 million.
    • Exceptional item on account of new labour code impact was Rs 254 million.
  • PAT (Profit After Tax) was Rs 928 million, with PAT margins at 20.3%.

Ajay Bhardwaj, Chairman, MD & CEO, Anthem Biosciences, said: “Our 9MFY26 performance has shown steady progress in revenue terms and with improving margin profile our EBITDA has grown at 23% and PBT before exceptional items has grown around 20%. Our quarterly revenue performance was influenced by the higher base of the same quarter last year, although the margin improvement neutralised the revenue shortfall. The underlying demand remains robust, with our historically strongest quarter still ahead, we are confident of delivering a strong finish to the financial year.”

Result PDF

Pharmaceuticals company Anthem Biosciences announced Q1FY26 results

  • Consolidated Revenue from Operations was Rs 5,402 million for the quarter.
    • CRDMO business delivered Rs 4,527 million revenues.
    • Specialty Ingredients delivered Rs 875 million revenues.
  • EBITDA was Rs 2,143 million, with EBITDA margins at 38%.
  • PAT (Profit After Tax)was Rs 1,358 million, with PAT margins at 24%.
  • Net Cash position as of June 30, 2025, is Rs 7,848 million.

Ajay Bhardwaj, Chairman, Managing Director & CEO, Anthem Biosciences, said: “We have kicked off FY26 with a strong performance, laying a solid foundation for the year ahead. Strong YoY growth in Q1FY26 reflects a CRDMO revenue stream that started ramping up since Q2FY25. A combination of a dedicated team, strategic focus, operational excellenceand long-standing client partnerships has helped us deliver performance across both CRDMO and Specialty Ingredients business”.

Result PDF

Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Download App

Download Our App

Get it on google Play Store Download on the App Store
market app